LEGN today
$17.50-$1.04 (-5.61%)close Nov 13, 2026Trend
DailyUptrend (starting)
4 hourStrong Bearish
1 hourExpanding
15 minStrong Bearish
5 minBearish
Daily trend turns down below $16.86
Key levels
Resistance$20.91
Resistance$18.00
Support$16.24
Latest news & SEC filings
AnalystOppenheimer keeps Perform rating on Legend Biotech, cuts price target to $25
AnalystMorgan Stanley keeps Overweight on Legend Biotech, cuts target to $43
All LEGN news →About Legend Biotech
Legend Biotech is a clinical-stage biopharmaceutical company that develops cell therapies for cancer. Its lead product is CARVYKTI (ciltacabtagene autoleucel), a CAR-T therapy for multiple myeloma, developed and commercialized in collaboration with Janssen Biotech, a Johnson & Johnson company. The company operates through subsidiaries in the United States, China, and the European Union, and is headquartered in Cayman Islands as a holding company.
Based on the company's 20-F filed Mar 10, 2026.
Nasdaq · Healthcare
Legend Biotech Corp (LEGN)
What Is the Price Target for LEGN?
SEPT Low Target
$24.00
SEPT Mid Target
$49.00
SEPT High Target
$68.00
Analyst Consensus
$49.00
Is LEGN a Buy or Sell Right Now?
Thesis
- •Revenue growing 64.0% YoY with STRONG trend — consistent growth.
AI-Powered Trading Signals
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for LEGN.
Start Free Trial →Is LEGN Overvalued or Undervalued?
Valuation Verdict
UNDERVALUED
Methods Used
Analyst Consensus
Fair Value
$49.00
20
Moat Score
NONE
2/9
Piotroski Score
7.8
Altman Z-Score
What Is Smart Money Doing with LEGN?
Insider Signal
SELLING
0 buys / 4 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
N/A
Short Squeeze Risk
HIGH
Signal: HIGH_SHORT_INTEREST
Recent Insider Activity
| Name | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
| Sanders Corazon (Corsee) D. | director | Sale | 27,370 | $259K | Sep 29, 2026 |
| Sanders Corazon (Corsee) D. | director | Buy | 20,986 | - | Sep 24, 2026 |
| Mao Li | director | Buy | 20,986 | - | Sep 24, 2026 |
| Salovey Peter | director | Buy | 28,330 | - | Sep 24, 2026 |
| Casey Patrick John | director | Buy | 20,986 | - | Sep 24, 2026 |
| Ji Darren Xiaohui | director | Buy | 28,330 | - | Sep 24, 2026 |
| Heyman Tomas J. | director | Buy | 20,986 | - | Sep 24, 2026 |
| Santos Carlos E | officer | Buy | 19,676 | - | Sep 21, 2026 |
| Santos Carlos E | officer | Sale | 5,430 | $50K | Sep 21, 2026 |
| Casey Patrick John | director | Sale | 6,000 | $89K | Jun 30, 2026 |
Track Smart Money Across 4,000+ Stocks
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →LEGN Growth Story
Revenue YoY
64.0%
3yr Revenue CAGR
106.4%
EPS Growth YoY
-68.75%
FCF Growth YoY
18.5%
Revenue Trend
STRONG
Dark Pool Trades for LEGN
PREVIEWSEPT Investing tracks real-time dark pool institutional trades for LEGN, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 21:01:00 | $17.50 | 14,780 | $$259K | SELL |
| 21:00:50 | $17.50 | 28,389 | $$497K | SELL |
| 21:00:25 | $17.50 | 3,258 | $$57K | SELL |
| 21:00:25 | $17.50 | 1,178 | $$21K | SELL |
| 20:58:46 | $17.49 | 1,900 | $$33K | BUY |
5 dark pool trades shown · $$866K preview volume
Real-time institutional flow, block trades, and net positioning
Options Flow for LEGN
PREVIEWSEPT Investing provides real-time options flow tracking for LEGN, including unusual sweep detection, block trades, and dealer positioning. Each trade shows strike, expiry, premium, implied volatility, and greek values for informed decision-making.
| Type | Strike | Expiry | DTE | Premium | Size | Trade |
|---|---|---|---|---|---|---|
| PUT | $20 | Dec 18 | 35 | $$285 | 1 | SWEEP |
| PUT | $20 | Dec 18 | 35 | $$285 | 1 | SWEEP |
| PUT | $20 | Dec 18 | 35 | $$285 | 1 | SWEEP |
| PUT | $20 | Dec 18 | 35 | $$285 | 1 | SWEEP |
| PUT | $20 | Dec 18 | 35 | $$285 | 1 | SWEEP |
5 options trades shown · 0% calls
Unusual activity, GEX levels, max pain, and dealer positioning
What Traders Are Saying About LEGN
2 postsSEPT Investing hosts an active community of 3,500+ traders sharing real-time analysis, trade setups, and market discussion for LEGN. Join verified traders discussing price action, dark pool alerts, options flow, and AI-powered market intelligence.
$LEGN: Morgan Stanley keeps Overweight on Legend Biotech, cuts target to $43
SEPT Brain on $LEGN -- Bearish Breakout above $26.45 from 79-day base. Uptrend holds while above $30.40. $40 psychological level is the next resistance to watch. The Play: Three scenarios from here:...
Join 3,500+ traders discussing LEGN in real-time
Trade ideas, setups, dark pool alerts, and AI-powered analysis
Full AI Research Report
SEPT's Trading AI has generated a free, downloadable PDF research report for Legend Biotech Corp (LEGN) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (3 articles analyzed), and SEC filing intelligence...
AI-Powered Trading Signals.
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →LEGN — frequently asked questions
What is LEGN stock price today?
Legend Biotech Corp (LEGN) is at $17.50, down 5.61% (-$1.04) at the Nov 13, 2026 close.
Why is LEGN stock moving today?
Latest LEGN news — Nov 11, 2026: Oppenheimer keeps Perform rating on Legend Biotech, cuts price target to $25 · Nov 11, 2026: Morgan Stanley keeps Overweight on Legend Biotech, cuts target to $43
Why did LEGN stock move on Nov 10, 2026?
Legend Biotech reported third-quarter 2026 financial results, posting an adjusted profit of $0.14 per share that beat the consensus estimate of $0.00, while revenue of $359.5 million came in just below the $361.619 million analysts expected. Despite the earnings beat, the stock fell 4.31% on the day, closing at $20.41 after trading between a low of $19.76 and a high of $22.85 on volume of over 6.2 million shares.
What is the LEGN price target?
The average analyst price target for LEGN is $49.00, ranging from $24 to $68, based on 9 analysts. Latest: Barclays maintains on Oct 13, 2026.
What do analysts rate LEGN?
Analyst ratings for LEGN: 0 Buy, 19 Hold, 2 Sell — consensus Hold.
Did LEGN beat earnings?
LEGN last reported on Nov 10, 2026: EPS $0.14 vs $0.00 expected — a beat.
Does LEGN pay a dividend?
LEGN does not currently pay a dividend.
How much debt does LEGN have?
Legend Biotech Corp reported $319M of debt and $902M of cash (Dec 31, 2025).
What are LEGN support and resistance levels?
Support: $16.24. Resistance: $18.00, $20.91, $24.42.
What are insiders doing with LEGN?
Insider activity: SELLING, 0 buys and 4 sells in the last 90 days.
What is the latest news on LEGN?
Nov 11, 2026: Oppenheimer keeps Perform rating on Legend Biotech, cuts price target to $25 · Nov 11, 2026: Morgan Stanley keeps Overweight on Legend Biotech, cuts target to $43